Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics

World Health Organization (WHO)

The World Health Organization was requested by Member States to develop a global priority pathogens list (global PPL) of antibiotic-resistant bacteria to help in prioritizing the research and development (R&D) of new and effective antibiotic treatments. To date, the selection of pathogens for R&D activities has been largely guided by small and large pharmaceutical companies according to a variety of parameters, such as perceived/unmet medical need, pressure of investors, market size, scientific discovery potential, and availability of specific technologies. 

February 28, 2017
Year of publication
Resource types
Guidelines and Policies, Programmatic guidance
global health threats, antibiotic resistance, World Health Organization, WHO, pathogens, drug resistance, treatment, TB treatment, drug-resistant tuberculosis (DR-TB), infectious diseases

Similar Resources

This guide from the Aurum Institute on the management of TB has been designed as a tool to make the diagnosis and management of TB simple and easy to implement at primary health care facilities. It can also be used for in-service training and as a mentorship tool.

Tuberculosis is now the world's commonest cause of death from infectious disease. The ominous spread of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, and the scarce treatment options available, are priority global health issues. With a global estimate in 2014 of…

Adequate management of drug-resistant tuberculosis (TB), including multidrug- (MDR-) and extensively drug-resistant (XDR-)TB are within the priorities of the newly launched World Health Organization's End TB and Elimination Strategies.

Prisoners and detainees worldwide have higher burdens of HIV, viral hepatitis, and tuberculosis than the communities from which they come. This disease burden among prisoners has been recognised since the early years of these inter-related pandemics.

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

To understand how HIV stigma operates and how it can be reduced, researchers need a standardised measurement framework. 

As children living with HIV (CLHIV) grow into adolescence and adulthood, caregivers and healthcare providers are faced with the sensitive challenge of when to disclose to a CLHIV his or her HIV status.

This guide is one of a series of good practice guides, and contains information, strategies and resources to help HIV programmers implement HIV programming for adolescents.

Two documents have been developed. The first provides a quick reference and summary of the main aspects related to supporting antiretroviral therapy adherence for HIV positive adolescents and young adults…

HIV-related stigma and discrimination in health care settings are known to negatively affect the HIV response.